A new era in migraine treatment begins now
Mentari Therapeutics is advancing a robust pipeline of next-generation biologics for the prevention of migraine—one of the most widespread and undertreated neurological conditions, affecting more than 1 billion people globally.
Our Focus
Redefining what's possible for people living with migraine
We are developing a new generation of targeted biologics for the prevention of migraine.
The arrival of therapies targeting calcitonin gene-related peptide (CGRP) marked a turning point in migraine care. Yet significant unmet need remains, with many people continuing to experience frequent and debilitating migraine attacks despite available treatments.
The need to transform migraine care is clear:
- Opportunity for meaningful improvement: An estimated 40-50% of people on anti-CGRP therapies do not achieve 50% or greater reduction in monthly migraine days1
- Significant global impact: More than 1 billion people worldwide live with migraine, many of whom remain inadequately served by available treatments
Science & Pipeline
Next-generation biologics designed for best-in-class efficacy, convenience, and safety
We are targeting validated pathways in migraine biology with a pipeline of bispecific antibodies and monoclonal antibodies. Our lead programs target pituitary adenylate cyclase-activating polypeptide (PACAP) and calcitonin gene-related peptide (CGRP), and our broader pipeline features additional targets with the potential to transform migraine treatment.
Our Approach
Validated biology, new opportunities
The PACAP pathway is distinct from CGRP signaling, with its therapeutic potential supported by two Phase 2 clinical studies of an anti-PACAP antibody.2
Dual-pathway inhibition
We believe bispecifics represent the next frontier in migraine treatment. Our first bispecific program targets PACAP and CGRP, with potential to deliver greater efficacy than targeting either pathway alone.
Patient-centric convenience
Our portfolio incorporates half-life extension designed to enable convenient, infrequent subcutaneous dosing to reduce treatment burden.
Diversified portfolio
Five programs targeting key pathways in migraine biology, including innovative bispecifics and monoclonal antibodies, providing the potential to address the broad needs of people living with migraine.
Our Pipeline
MT-001
MT-002
MT-003
MT-004
MT-005
SC= Subcutaneous
Our Lead Programs
About MT-001
- Investigational anti-PACAP monoclonal antibody (mAb) designed to block PACAP with potential for best-in-class efficacy
- Engineered with an effector-null IgG1 Fc and a clinically validated half-life extension modification, designed to support convenient, infrequent subcutaneous dosing
About MT-002
- Investigational bispecific antibody designed to block both PACAP and CGRP, with the potential to deliver greater efficacy compared to either pathway alone
- Combines a validated CGRP-binding approach with potent PACAP inhibition and incorporates a clinically validated half-life extension modification in a 1+1 IgG-like format, designed to support monoclonal antibody-like pharmacokinetics and infrequent convenient subcutaneous dosing
Who we are
Deep expertise in antibody engineering and drug development
We are a team of seasoned biotech leaders, passionate scientists, and industry veterans with a proven track record developing biologics.
Join Our Team
United by a single purpose, we are working to bring freedom from migraine to as many people as possible. We are seeking new team members who share our commitment to innovative science that can improve lives.
See Open Roles
